Ovidiu

Romania

34 total trials 17 recruiting

Filter these 34 trials by phase, condition, sponsor and more.

Open in Search →

A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce … Ended recruitment

2023-509943-28-00 5 2022-05-18 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance … Ended recruitment

2023-509133-39-00 5 2021-11-29 Hormone receptor positive, HER2-negative advanced breast cancer
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment

2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended

2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J … Ended

2023-505457-40-00 5 2022-02-02 Previously Untreated Advanced Gastric or Gastroesophageal Junction Can
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended

2022-501342-29-00 5 2021-07-21 Esophageal Carcinoma
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 5 2019-06-26 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 5 2019-06-25 Stage IV lung cancer condition

Showing 25–34 of 34 trials